ADC Payload and Linker Supply Assessment: Preview Report
A free preview of how ProGen's assessment of ADC payload, linker-payload and conjugation supply is built, down to the fields each record carries. It maps who holds each of the four places an ADC is made, by site, country and payload class, traces approved ADCs to the sites named for them, and reads the demand signal from the registered clinical pipeline. Results are reserved for buyers.
Built to order · Research cut-off: 18 November 2026

What this report answers
- Which suppliers can make each payload class and linker-payload, under containment and at commercial scale?
- How is each manufacturing site recorded, and how is announced capacity told apart from qualified supply?
- How is each approved ADC checked against the sites named for it?
- How is the demand signal for each payload class read from the clinical pipeline?
- What does a buyer of the full assessment receive?
65 supplier site records
Across 53 companies in 14 countries and territories, each with five nodes recorded and one of four capacity states.
1,875 registered ADC trials
Sorted by payload class where the payload is public, 1,144 of them active.
What the analysis establishes
Four places, six payload classes
Payload and linker-payload, antibody, conjugation and drug product are recorded separately, so a supplier that holds one node is never read as holding the chain. Six payload classes are read across the chain: auristatins, topoisomerase I inhibitors, maytansinoids, PBD dimers, calicheamicins and other classes.
The supplier register
65 supplier site records across 53 companies in 14 countries and territories. Each records five nodes, containment and scale where stated, and one of four capacity states: announced, built, GMP clinical supply or commercial supply. A company statement about itself is kept apart from third-party evidence.
From product to site
21 approved ADCs profiled, 13 of them traced through European regulator records to their named drug-substance and batch-release sites, with company filings and listing documents for payload and drug-linker sources. Each product record asks three questions: single source, second route and what requalification would need.
Demand from the clinical pipeline
1,875 registered ADC trials identified, 1,144 of them active, sorted by payload class where the payload is public and cut by phase, status, start year and sponsor country, with registry identifiers retained. The preview shows the structure; values are withheld.
Built to your decision
Each assessment is scoped to the decision in front of you, whether one asset, a portfolio, a supplier choice or an investment, and quoted on request.
About this intelligence
More than 440 evidence records from more than 240 public sources, each with a date, alongside 59 dated capacity, deal and licensing events. Sources include public registries, regulator records, company filings and disclosures. Other sources are proprietary ProGen intelligence sources. Evidence is current to 18 November 2026.
Investors testing supply risk behind an ADC asset or platform. Developers choosing a payload source, conjugation partner or second source. Corporate development teams assessing a CDMO or a licensing partner. CDMOs reading the clinical pipeline by payload class against qualified supply.
Contents
- Why an ADC supply assessment
- The questions it answers
- How the assessment is built
- The chain: four places
- Six payload classes
- The supplier register
- Capacity states
- Dependencies: from product to site
- Demand: the clinical pipeline
- Capacity and deals
- Exposure: geography and supply security
- Release testing
- The evidence base
- What a buyer receives
Payload classes covered
Auristatins, Topoisomerase I inhibitors, Maytansinoids, PBD dimers, Calicheamicins, Other classes
The full 8-page briefing is free. Tell us where to send it and it downloads immediately.
ADC Payload and Linker Supply Assessment
Built to your question and quoted individually: who can make payloads, linker-payloads and conjugates at scale, and where the bottlenecks sit.
See the analysis →